Enasidenib efficiently suppressed 2-HG production and inhibited proliferation of IDH2R140Q- and IDH2R172K-mutant but not IDH2-wild-type AML cell lines and IDH2R140Q-mutant primary AML compared to vehicle and WT AML (Supplementary Figure 8c). The gene discussed is IDH2; the disease is acute myeloid leukemia.